No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages 4299-4306

  Winhofer, Yvonne ^a   Wolf, Peter ^a   Krššák, Martin ^a,b   Wolfsberger, Stefan ^a   Tura, Andrea ^c   Pacini, Giovanni ^c   Gessl, Alois ^a   Raber, Wolfgang ^a   Kukurova, Ivica Just ^b   Kautzky Willer, Alexandra ^a   Knosp, Engelbert ^a   Trattnig, Siegfried ^b   Krebs, Michael ^a   Luger, Anton ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Center of Excellence   (Austria)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID;

ACROMEGALIC CARDIOMYOPATHY; ACROMEGALY; ADULT; ARTICLE; BODY MASS; CARDIOMYOPATHY; CLINICAL ARTICLE; FEMALE; HEART HYPERTROPHY; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART STROKE VOLUME; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID COMPOSITION; LIPID LIVER LEVEL; LIPID OXIDATION; LIPID STORAGE; MALE; MULTICENTER STUDY; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSSPHENOIDAL SURGERY; COMPLICATION; HEART MUSCLE; LIPID METABOLISM; LIVER; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

ACROMEGALY; ADULT; CARDIOMYOPATHIES; FEMALE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; LIVER; MALE; MIDDLE AGED; MYOCARDIUM; RISK FACTORS;

EID: 84910020567     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2242     Document Type: Article

References (51)

1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Rev. 2004; 25: 102-152.
2. Luger A, Prager R, Gaube S, Graf H, Klauser R, Schernthaner G. Decreased peripheral insulin sensitivity in acromegalic patients. Exp Clin Endocrinol. 1990; 95: 339-343.
3. Moller N, Gormsen LC, Schmitz O, Lund S, Jorgensen JO, Jessen N. Free fatty acids inhibit growth hormone/signal transducer and activator of transcription-5 signaling in human muscle: a potential feedback mechanism. J Clin Endocrinol Metab. 2009; 94: 2204-2207.
4. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009; 30: 152-177.
5. Moller N, Butler PC, Antsiferov MA, Alberti KG. Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia. 1989; 32: 105-110.
6. O'Sullivan AJ, Kelly JJ, Hoffman DM, Freund J, Ho KK. Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab. 1994; 78: 381-386.
7. Freda PU, Shen W, Heymsfield SB, et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab. 2008; 93: 2334-2343.
8. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987; 26: 481-512.
9. Sonksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A, Nabarro JD. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab. 1967; 27: 1418-1430.
10. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003; 14: 281-287.
11. Szendroedi J, Roden M. Ectopic lipids and organ function. Curr Opin Lipidol. 2009; 20: 50-56.
12. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 2010; 1801: 209-214.
13. Szendroedi J, Zwettler E, Schmid AI, et al. Reduced basal ATP synthetic flux of skeletal muscle in patients with previous acromegaly. PloS One. 2008; 3: e3958.
14. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf). 2008; 69: 347-358.
15. Colao A, Vitale G, Pivonello R, Ciccarelli A, DiSommaC, Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol. 2004; 151(suppl 1): S93-S101.
16. Hammer S, Snel M, Lamb HJ, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol. 2008; 52: 1006-1012.
17. Hammer S, van der Meer RW, Lamb HJ, et al. Progressive caloric restriction induces dose-dependent changes in myocardial triglyceride content and diastolic function in healthy men. J Clin Endocrinol Metab. 2008; 93: 497-503.
18. Winhofer Y, Krssak M, Jankovic D, et al. Short-term hyperinsulinemia and hyperglycemia increase myocardial lipid content in normal subjects. Diabetes. 2012; 61: 1210-1216.
19. Jankovic D, Winhofer Y, Promintzer-Schifferl M, et al. Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus. PloS One. 2012; 7: e50077.
20. Krssak M, Hofer H, Wrba F, et al. Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy. Eur J Radiol. 2010; 74: e60-e66.
21. Rijzewijk LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008; 52: 1793-1799.
22. van der Meer RW, Doornbos J, Kozerke S, et al. Metabolic imagingof myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology. 2007; 245: 251-257.
23. Krssak M, Winhofer Y, Gobl C, et al. Insulin resistance is not associated with myocardial steatosis in women. Diabetologia. 2011; 54: 1871-1878.
24. Krssak M, Mlynarik V, Meyerspeer M, Moser E, Roden M. 1H NMR relaxation times of skeletal muscle metabolites at 3 T. Magma. 2004; 16: 155-159.
25. Velagaleti RS, Gona P, Chuang ML, et al. Relations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: the Framingham Heart Study. Circ Cardiovasc Imaging. 2010; 3: 257-263.
26. Waiter GD, McKiddie FI, Redpath TW, Semple SI, Trent RJ. Determination of normal regional left ventricular function from cine-MR images using a semi-automated edge detection method. Magn Reson Imaging. 1999; 17: 99-107.
27. Schiller NB, Shah PM, Crawford M, et al et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2: 358-367.
28. Iozzo P, Lautamaki R, Borra R, et al. Contribution of glucose tolerance and gender to cardiac adiposity. J Clin Endocrinol Metab. 2009; 94: 4472-4482.
29. Tura A, Ludvik B, Nolan JJ, Pacini G, Thomaseth K. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. Am J Physiol Endocrinol Metab. 2001; 281: E966-E974.
30. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001; 24: 539-548.
31. Anderwald C, Bernroider E, Krssak M, et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes. 2002; 51: 3025-3032.
32. Levelt E, Ntusi N, Mahmod M, et al. 127 Early manifestations of diabetic cardiomyopathy assessed by cardiac magnetic resonance imaging and spectroscopy. Heart. 2014; 100(suppl 3): A73-A74.
33. Szendroedi J, Anderwald C, Krssak M, et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care. 2009; 32: 209-214.
34. Phielix E, Brehm A, Bernroider E, et al. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes. Diabetes Obes Metab. 2013; 15: 915-922.
35. Krssak M, Brehm A, Bernroider E, et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes. 2004; 53: 3048-3056.
36. Bredella MA, Torriani M, Thomas BJ, et al. Peak growth hormonereleasing hormone-arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity. J Clin Endocrinol Metab. 2009; 94: 3995-4002.
37. Bredella MA, Gerweck AV, Lin E, et al. Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity. J Clin Endocrinol Metab. 2013; 98: 3864-3872.
38. Moller N, Schmitz O, Joorgensen JO, et al. Basal-and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab. 1992; 74: 1012-1019.
39. Katznelson L. Alterations in body composition in acromegaly. Pituitary. 2009; 12: 136-142.
40. Miller KK, Wexler T, Fazeli P, et al. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab. 2010; 95: 567-577.
41. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009; 106: 15430-15435.
42. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008; 168: 1609-1616.
43. Ehrnborg C, Ellegard L, Bosaeus I, Bengtsson BA, Rosen T. Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults. Clin Endocrinol (Oxf). 2005; 62: 449-457.
44. Moller J, Jorgensen JO, Frandsen E, Laursen T, Christiansen JS. Body fluids, circadian blood pressure and plasma renin during growth hormone administration: a placebo-controlled study with two growth hormone doses in healthy adults. Scand J Clin Lab Invest. 1995; 55: 663-669.
45. Petersen KF, West AB, Reuben A, Rothman DL, Shulman GI. Noninvasive assessment of hepatic triglyceride content in humans with 13C nuclear magnetic resonance spectroscopy. Hepatology. 1996; 24: 114-117.
46. Kasayama S, Otsuki M, Takagi M, et al. Impairedβ-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf). 2000; 52: 549-555.
47. Andreassen M, Faber J, Kjaer A, Petersen CL, Kristensen LO. Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides. Pituitary. 2010; 13: 329-336.
48. Bogazzi F, Lombardi M, Strata E, et al. Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance. J Endocrinol Invest. 2010; 33: 103-108.
49. Colao A. Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary. 2012; 15: 50-58.
50. Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab. 2001; 86: 1551-1557.
51. Colao A, Pivonello R, Grasso LF, et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol. 2011; 165: 713-721.